Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 368

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 368
---
 units operate at the forefront of scientific development, genetic testing and will be integrated with AI -driventechnology, designed to address the entire spectrum of healthcare needs, spanning prevention diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data. The services within these segments have been developed based on our experience in Latin America, allowing us to adapt our tests and results based on local language and specific needs. With a focus on precision, privacy, and accessibility, OmnigenicsAI is committed to empowering individuals and healthcare providers with the tools necessary for proactive health management through the following categories with its current brands: • Rewell: personalized wellness and preventative health solutions that integrate genetic, microbiome and lifestyle data, with nutrigenetic guidance tailored to each user. Through our digital platform, users access DNA and gut microbiome testing, paired with personalized health recommendations designed to empower individuals in making informed health decisions, particularly for chronic disease prevention and gut health. Initially distributed as a direct -to-consumerproduct, in 2025, we expect to transition the distribution of Rewell to a business -to-business-to-consumerdistribution model. Rewell’s services include consultations with certified nutrigenetic specialists, which we plan to scale through the use of AI Agents, which are designed to support users in adopting lifestyle changes based on genetic and microbiome insights.; and •Heritas Diagnostics: a suite of clinical genetic testing services focused on reproductive health, oncology, rare diseases, and clinical gut health. Our tests integrate genetic and clinical data to provide precise and actionable insights that support accurate diagnoses, effective monitoring and informed treatment decisions. We ensure that our comprehensive clinical reports deliver the necessary insights needed by both patients and physicians to interpret results and make informed treatment decisions. To enhance accessibility and support, we plan to incorporate AI Agents, expected to have its first commercial use as early as 2026, that will assist patients in interpreting their results and providing personalized treatment recommendations, complementing physician guidance. Rewell: Wellness and Prevention We believe that Rewell will be at the forefront of wellness and prevention, enabling consumers to obtain personalized genetics and gut microbiome information, with nutrition recommendations and habit plans that support informed life changes that would mitigate disease initiation and development and improve overall wellbeing. Rewell’s proprietary platform provides personalized DNA and microbiome results by integrating customer’s genetic and lifestyle data and associated risk factors and comparing these results to both a standard and proprietary database. This aims at lowering the chances of developing low grade chronic inflammation over time, as Rewell